Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double …
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: 求助Supplementary appendix
其他信息:
求助Supplementary appendix
I Kaul, S Sawchak, CU Correll, R Kakar, A Breier…
The Lancet, 2024
thelancet.com
Background New treatments with new mechanisms are urgently needed for people with schizophrenia. Xanomeline is a dual M 1 and M 4-preferring muscarinic receptor agonist that does not block D 2 dopamine receptors, unlike all currently approved treatments for schizophrenia. Xanomeline–trospium (KarXT) combines xanomeline with the peripherally restricted muscarinic receptor antagonist trospium chloride with the goal of ameliorating xanomeline-related adverse events associated with peripheral muscarinic receptors. The …
